Report: Nearly half of mCRPC patients do not receive second-line therapy

Nearly half of men with metastatic castration-resistant prostate cancer (mCRPC) receive no second-line treatment, according to new findings, highlighting a potential care gap. (Exact figure not reported in source)

• The news report from AuntMinnie summarizes data presented at a medical meeting or published study (details not provided).
• Findings raise concerns about underuse of available therapies, including radiopharmaceuticals.

RadPigeon summaries are original and for information only. They are not clinical advice.